Taladegib

DB12550InvestigationalSmall molecule

Taladegib has been used in trials studying the treatment of Solid Tumor, COLON CANCER, BREAST CANCER, Advanced Cancer, and Rhabdomyosarcoma, among others.

Mechanism: Pharmacologically active on Protein smoothened
Curator reviewed
Formula / weight: C₂₆H₂₄F₄N₆O · 512.502 g/mol (avg)
Code names: ENV-101 · LY-2940680

Resolves to

Compound

UNIIQY8BWX1LJ5CAS1258861-20-9ChEMBLCHEMBL2142592PubChem49848070

Structure

InChIKeySZBGQDXLNMELTB-UHFFFAOYSA-NSMILESCN(C1CCN(CC1)C1=NN=C(C2=CC=NN2C)C2=CC=CC=C12)C(=O)C1=C(C=C(F)C=C1)C(F)(F)F

Targets

Q99835SMO

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Taladegib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account